Sildenafil 100 mg Tablets Relative to Viagra 100 mg Tablets
- Disease/Condition
- Healthy Subjects
- Drug/Device/Intervention
- Sildenafill-Test product
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Bio-innova Co., Ltd
- Phase
- Phase 1
- Start date
- Feb 04, 2025
- End date
- Mar 25, 2025
- Enrollment
- 36 participants
Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC 0-t),Maximal measured plasma concentration (Cmax)
The study is to compare the rate and extent of absorption of a generic formulation with that
 of a reference for mulation when given as equal labeled dose. The study will be randomized,
 open-label, single dose, two way crossover design with two-period, two-treatment and
 two-sequence under fasting condition and at least 3 days washout period between the doses.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06289881
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06289881 through Pure Global AI's free database. This Phase 1 trial is sponsored by Bio-innova Co., Ltd and is currently Not yet recruiting. The study focuses on Healthy Subjects. Target enrollment is 36 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.